BMP2 gene delivery to bone mesenchymal stem cell by chitosan-g-PEI nonviral vector

Nanoscale Research Letters

Volumn 10, Issue 1, 2015, Pages

  Yue, Jianhui ^a   Wu, Jun ^b   Liu, Di ^a,c   Zhao, Xiaoli ^a   Lu, William W ^b  

^a SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Chitosan; Gene delivery; Osteogenic differentiation; Polyethylenimine; Stem cell

Indexed keywords

BONE; CELL CULTURE; CHITOSAN; GENE THERAPY; GENE TRANSFER; MEDICAL NANOTECHNOLOGY; MOLECULAR BIOLOGY; VECTORS;

BONE MARROW STEM CELLS; BONE MESENCHYMAL STEM CELLS; GENE DELIVERY; NONVIRAL VECTORS; OSTEOGENIC DIFFERENTIATION; POLYETHYLENIMINES; TRANSFECTION EFFICIENCY; TRANSGENE EXPRESSION;

STEM CELLS;

EID: 84928905701     PISSN: 19317573     EISSN: 1556276X     Source Type: Journal    
DOI: 10.1186/s11671-015-0906-3     Document Type: Article

References (55)

1. Lo KW, Ulery BD, Ashe KM, Laurencin CT. Studies of bone morphogenetic protein-based surgical repair. Adv Drug Deliv Rev. 2012;64(12):1277–91.
2. Shi JJ, Votruba AR, Farokhzad OC, Langer R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett. 2010;10(9):3223–30.
3. Tannoury CA, An HS. Complications with the use of bone morphogenetic protein 2 (BMP-2) in spine surgery. Spine J. 2014;14(3):552–9.
4. Ronga M, Fagetti A, Canton G, Paiusco E, Surace MF, Cherubino P. Clinical applications of growth factors in bone injuries: experience with BMPs. Injury. 2013;44 Suppl 1:S34–9.
5. Evans CH, Ghivizzani SC, Robbins PD. Progress and prospects: genetic treatments for disorders of bones and joints. Gene Ther. 2009;16(8):944–52.
6. Kimelman Bleich N, Kallai I, Lieberman JR, Schwarz EM, Pelled G, Gazit D. Gene therapy approaches to regenerating bone. Adv Drug Deliv Rev. 2012;64(12):1320–30.
7. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med. 2013;15(2):65–77.
8. Hackett PB, Largaespada DA, Switzer KC, Cooper LJ. Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Transl Res. 2013;161(4):265–83.
9. Elsabahy M, Nazarali A, Foldvari M. Non-viral nucleic acid delivery: key challenges and future directions. Curr Drug Deliv. 2011;8(3):235–44.
10. Lam AP, Dean DA. Progress and prospects: nuclear import of nonviral vectors. Gene Ther. 2010;17(4):439–47.
11. Kawai M, Bessho K, Kaihara S, Sonobe J, Oda K, Iizuka T, et al. Ectopic bone formation by human bone morphogenetic protein-2 gene transfer to skeletal muscle using transcutaneous electroporation. Hum Gene Ther. 2003;14(16):1547–56.
12. Kirtane AR, Panyam J. Polymer nanoparticles weighing up gene delivery. Nat Nanotechnol. 2013;8(11):805–6.
13. Saranya N, Moorthi A, Saravanan S, Devi MP, Selvamurugan N. Chitosan and its derivatives for gene delivery. Int J Biol Macromol. 2011;48(2):234–8.
14. Patnaik S, Gupta KC. Novel polyethylenimine-derived nanoparticles for in vivo gene delivery. Expert Opin Drug Del. 2013;10(2):215–28.
15. Yamano S, Dai J, Hanatani S, Haku K, Yamanaka T, Ishioka M, et al. Long-term efficient gene delivery using polyethylenimine with modified Tat peptide. Biomaterials. 2014;35(5):1705–15.
16. Moghimi SM, Symonds P, Murray JC, Hunter AC, Debska G, Szewczyk A. A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Mol Ther. 2005;1(6):990–5.
17. Yu YY, Wang Z, Cai L, Wang G, Yang X, Wan XP, et al. Synthesis and characterization of methoxy poly(ethylene glycol)-O-chitosan-polyethylenimine for gene delivery. Carbohydr Polym. 2010;81(2):269–74.
18. Peng YS, Lai PL, Peng S, Wu HC, Yu S, Tseng TY, et al. Glial cell line-derived neurotrophic factor gene delivery via a polyethylene imine grafted chitosan carrier. Int J Nanomed. 2014;9:3163–74.
19. Ping Y, Liu C, Zhang Z, Liu KL, Chen J, Li J. Chitosan-graft-(PEI-beta-cyclodextrin) copolymers and their supramolecular PEGylation for DNA and siRNA delivery. Biomaterials. 2011;32(32):8328–41.
20. Jiang HL, Kwon JT, Kim EM, Kim YK, Arote R, Jere D, et al. Galactosylated poly(ethylene glycol)-chitosan-graft-polyethylenimine as a gene carrier for hepatocyte-targeting. J Control Release. 2008;131(2):150–7.
21. Jiang HL, Xu CX, Kim YK, Arote R, Jere D, Lim H-T, et al. The suppression of lung tumorigenesis by aerosol-delivered folate–chitosan-graft-polyethylenimine/Akt1 shRNA complexes through the Akt signaling pathway. Biomaterials. 2009;30(29):5844–52.
22. Jiang HL, Kim YK, Arote R, Jere D, Quan JS, Yu J-H, et al. Mannosylated chitosan-graft-polyethylenimine as a gene carrier for Raw 264.7 cell targeting. Int J Pharm. 2009;375(1–2):133–9.
23. Jiang HL, Kwon JT, Kim YK, Kim EM, Arote R, Jeong HJ, et al. Galactosylated chitosan-graft-polyethylenimine as a gene carrier for hepatocyte targeting. Gene Ther. 2007;14(19):1389–98.
24. Jia LJ, Li ZY, Zhang DR, Zhang Q, Shen JY, Guo HJ, et al. Redox-responsive catiomer based on PEG-ss-chitosan oligosaccharide-ss-polyethylenimine copolymer for effective gene delivery. Polym Chem Uk. 2013;4(1):156–65.
25. Liu CC, Zhu Q, Wu WH, Xu XL, Wang XY, Gao S, et al. Degradable copolymer based on amphiphilic N-octyl-N-quatenary chitosan and low-molecular weight polyethylenimine for gene delivery. Int J Nanomed. 2012;7:5339–50.
26. Lu B, Xu XD, Zhang XZ, Cheng SX, Zhuo RX. Low molecular weight polyethylenimine grafted N-maleated chitosan for gene delivery: properties and in vitro transfection studies. Biomacromolecules. 2008;9(10):2594–600.
27. Tripathi SK, Goyal R, Kumar P, Gupta KC. Linear polyethylenimine-graft-chitosan copolymers as efficient DNA/siRNA delivery vectors in vitro and in vivo. Nanomedicine. 2012;8(3):337–45.
28. Jere D, Jiang H-L, Kim YK, Arote R, Choi Y-J, Yun C-H, et al. Chitosan-graft-polyethylenimine for Akt1 siRNA delivery to lung cancer cells. Int J Pharm. 2009;378(1–2):194–200.
29. Huh MS, Lee SY, Park S, Lee S, Chung H, Lee S, et al. Tumor-homing glycol chitosan/polyethylenimine nanoparticles for the systemic delivery of siRNA in tumor-bearing mice. J Control Release. 2010;144(2):134–43.
30. Gao JQ, Zhao QQ, Lv TF, Shuai WP, Zhou J, Tang GP, et al. Gene-carried chitosan-linked-PEI induced high gene transfection efficiency with low toxicity and significant tumor-suppressive activity. Int J Pharm. 2010;387(1–2):286–94.
31. Hu FQ, Chen WW, Zhao MD, Yuan H, Du YZ. Effective antitumor gene therapy delivered by polyethylenimine-conjugated stearic acid-g-chitosan oligosaccharide micelles. Gene Ther. 2013;20(6):597–606.
32. Lu HD, Dai YH, Lv LL, Zhao HQ. Chitosan-graft-polyethylenimine/DNA nanoparticles as novel non-viral gene delivery vectors targeting osteoarthritis. PLoS One. 2014;doi:10.1371/journal.pone.0084703.
33. Zhao XL, Li ZY, Pan HB, Liu WG, Lv MM, Leung F, et al. Enhanced gene delivery by chitosan-disulfide-conjugated LMW-PEI for facilitating osteogenic differentiation. Acta Biomater. 2013;9(5):6694–703.
34. Yang HY, Vonk LA, Licht R, van Boxtel AMG, Bekkers JEJ, Kragten AHM, et al. Cell type and transfection reagent-dependent effects on viability, cell content, cell cycle and inflammation of RNAi in human primary mesenchymal cells. Eur J Pharm Sci. 2014;53:35–44.
35. Holladay C, Keeney M, Greiser U, Murphy M, O’Brien T, Pandit A. A matrix reservoir for improved control of non-viral gene delivery. J Control Release. 2009;136(3):220–5.
36. Park J, Ries J, Gelse K, Kloss F, von der Mark K, Wiltfang J, et al. Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: a comparison of adenoviral vectors and liposomes. Gene Ther. 2003;10(13):1089–98.
37. Lu K, Zeng D, Zhang Y, Xia L, Xu L, Kaplan DL, et al. BMP-2 gene modified canine bMSCs promote ectopic bone formation mediated by a nonviral PEI derivative. Ann Biomed Eng. 2011;39(6):1829–39.
38. Zhu H, Guo ZK, Jiang XX, Li H, Wang XY, Yao HY, et al. A protocol for isolation and culture of mesenchymal stem cells from mouse compact bone. Nat Protoc. 2010;5(3):550–60.
39. Ohyama M, Okano H. Promise of human induced pluripotent stem cells in skin regeneration and investigation. J Invest Dermatol. 2014;134(3):605–9.
40. Hamm A, Krott N, Breibach I, Blindt R, Bosserhoff AK. Efficient transfection method for primary cells. Tissue Eng. 2002;8(2):235–45.
41. Abdallah B, Hassan A, Benoist C, Goula D, Behr JP, Demeneix BA. A powerful nonviral vector for in vivo gene transfer into the adult mammalian brain: polyethylenimine. Hum Gene Ther. 1996;7(16):1947–54.
42. Lowery JW, de Caestecker MP. BMP signaling in vascular development and disease. Cytokine Growth Factor Rev. 2010;21(4):287–98.
43. Rosen V. BMP2 signaling in bone development and repair. Cytokine Growth Factor Rev. 2009;20(5–6):475–80.
44. Sieber C, Kopf J, Hiepen C, Knaus P. Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev. 2009;20(5–6):343–55.
45. Lee KS, Hong SH, Bae SC. Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-beta and bone morphogenetic protein. Oncogene. 2002;21(47):7156–63.
46. Kumar S, Wan C, Ramaswamy G, Clemens TL, Ponnazhagan S. Mesenchymal stem cells expressing osteogenic and angiogenic factors synergistically enhance bone formation in a mouse model of segmental bone defect. Mol Ther. 2010;18(5):1026–34.
47. Granero-Moltó F, Weis JA, Miga MI, Landis B, Myers TJ, O’Rear L, et al. Regenerative effects of transplanted mesenchymal stem cells in fracture healing. Stem Cells. 2009;27(8):1887–98.
48. Kumar S, Nagy TR, Ponnazhagan S. Therapeutic potential of genetically modified adult stem cells for osteopenia. Gene Ther. 2010;17(1):105–16.
49. Hanada K, Dennis JE, Caplan AI. Stimulatory effects of basic fibroblast growth factor and bone morphogenetic protein-2 on osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells. J Bone Miner Res. 1997;12(10):1606–14.
50. Evans C. Gene therapy for the regeneration of bone. Injury. 2011;42(6):599–604.
51. Jane JA, Dunford BA, Kron A, Pittman DD, Sasaki T, Li JZ, et al. Ectopic osteogenesis using adenoviral bone morphogenetic protein (BMP)-4 and BMP-6 gene transfer. Mol Ther. 2002;6(4):464–70.
52. Gafni Y, Pelled G, Zilberman Y, Turgeman G, Apparailly F, Yotvat H, et al. Gene therapy platform for bone regeneration using an exogenously regulated, AAV-2-based gene expression system. Mol Ther. 2004;9(4):587–95.
53. Chen Y, Luk KDK, Cheung KMC, Xu R, Lin MC, Lu WW, et al. Gene therapy for new bone formation using adeno-associated viral bone morphogenetic protein-2 vectors. Gene Ther. 2003;10(16):1345–53.
54. Huang YC, Simmons C, Kaigler D, Rice KG, Mooney DJ. Bone regeneration in a rat cranial defect with delivery of PEI-condensed plasmid DNA encoding for bone morphogenetic protein-4 (BMP-4). Gene Ther. 2005;12(5):418–26.
55. Aslan H, Zilberman Y, Arbeli V, Sheyn D, Matan Y, Liebergall M, et al. Nucleofection-based ex vivo nonviral gene delivery to human stem cells as a platform for tissue regeneration. Tissue Eng. 2006;12(4):877–89.